Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-11.005)
To evaluate long-term safety and efficacy of efgartigimod PH20 SC in participants with generalized myasthenia gravis (gMG) enrolled in the ADAPT-SC+ open-label extension (OLE).
Authors
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Sophie Steeland
- Jana Podhorna
- Denis Korobko
- Benjamin Van Hoorick
- Moana Hodari
- Yuebing Li (ORCID: https://orcid.org/0000-0002-4248-8927)
- Jan L. De Bleecker
Institutions
- Cleveland Clinic (US)
- University of South Florida (US)
- Ghent University Hospital (BE)
- Federico II University Hospital (IT)
- Krasnoyarsk Regional Clinical Hospital (RU)
- National Hospital Organization Hanamaki Hospital (JP)
- Argenx (Belgium) (BE)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210678
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00